186 related articles for article (PubMed ID: 36652179)
1. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.
Ikenaga N; Nakata K; Hayashi M; Nakamura S; Abe T; Ideno N; Murakami M; Fujimori N; Fujita N; Isoda T; Baba S; Ishigami K; Oda Y; Nakamura M
J Gastrointest Surg; 2023 Feb; 27(2):337-346. PubMed ID: 36652179
[TBL] [Abstract][Full Text] [Related]
2. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
Ariake K; Motoi F; Shimomura H; Mizuma M; Maeda S; Terao C; Tatewaki Y; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Takadate T; Naitoh T; Taki Y; Unno M
J Gastrointest Surg; 2018 Feb; 22(2):279-287. PubMed ID: 29119533
[TBL] [Abstract][Full Text] [Related]
3. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
[TBL] [Abstract][Full Text] [Related]
4. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy.
Suto H; Okano K; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Masaki T; Suzuki Y
J Surg Oncol; 2022 Aug; 126(2):292-301. PubMed ID: 35289928
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
7. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H
Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987
[TBL] [Abstract][Full Text] [Related]
8. The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer.
Crippa S; Salgarello M; Laiti S; Partelli S; Castelli P; Spinelli AE; Tamburrino D; Zamboni G; Falconi M
Dig Liver Dis; 2014 Aug; 46(8):744-9. PubMed ID: 24721105
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma.
Itchins M; Chua TC; Arena J; Jamieson NB; Nahm CB; O'Connell RL; Bailey EA; Schembri GP; Gill AJ; Kneebone A; Hruby G; Mittal A; Pavlakis N; Clarke SJ; Samra JS
Pancreas; 2020 Feb; 49(2):224-229. PubMed ID: 32011525
[TBL] [Abstract][Full Text] [Related]
10. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging?
Wartski M; Sauvanet A
Diagn Interv Imaging; 2019 Dec; 100(12):735-741. PubMed ID: 31402332
[TBL] [Abstract][Full Text] [Related]
12. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
13. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
[TBL] [Abstract][Full Text] [Related]
14. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
[TBL] [Abstract][Full Text] [Related]
15. Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results.
Kawada N; Tanaka S; Uehara H; Katayama K; Hosoki T; Takami M; Tomita Y
Hepatogastroenterology; 2014; 61(130):480-3. PubMed ID: 24901166
[TBL] [Abstract][Full Text] [Related]
16. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Choi M; Heilbrun LK; Venkatramanamoorthy R; Lawhorn-Crews JM; Zalupski MM; Shields AF
Am J Clin Oncol; 2010 Jun; 33(3):257-61. PubMed ID: 19806035
[TBL] [Abstract][Full Text] [Related]
17. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.
Xu HX; Chen T; Wang WQ; Wu CT; Liu C; Long J; Xu J; Zhang YJ; Chen RH; Liu L; Yu XJ
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1093-102. PubMed ID: 24522797
[TBL] [Abstract][Full Text] [Related]
18. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.
Takahashi M; Nojima H; Kuboki S; Horikoshi T; Yokota T; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
Pancreatology; 2020 Sep; 20(6):1205-1212. PubMed ID: 32819845
[TBL] [Abstract][Full Text] [Related]
19. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
